Thermo Fisher Scientific Inc. is investing over $50 million to grow its bioproduction capabilities.

The funds will be used to expand the company's capacity for making single-use bioprocess container systems, used for sterile liquid-handling applications. Such technologies help increase productivity and ensure quality in the production of biologic drugs, Waltham, Mass.-based Thermo Fisher said.

The company will expand assembly capacity and add bioprocess container systems manufacturing in Cramlington, U.K.

In the U.S., Thermo Fisher plans to grow cleanroom space for bioprocess container chamber and related assembly production processes in Logan, Utah, and further expand capacity in Millersburg, Penn.

Completion of construction is expected by 2020-end.